Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator

Stroke

Volumn 43, Issue 9, 2012, Pages 2293-2299

  Menon, Bijoy K ^a   Saver, Jeffrey L ^b   Prabhakaran, Shyam ^d   Reeves, Mathew ^e   Liang, Li ^f   Olson, Daiwai M ^f   Peterson, Eric D ^f   Hernandez, Adrian F ^f   Fonarow, Gregg C ^c   Schwamm, Lee H ^g   Smith, Eric E ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Department of Neurology ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

acute ischemic stroke; intravenous tPA; risk score; symptomatic intracranial hemorrhage

Indexed keywords

GLUCOSE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; ASIAN; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CALIBRATION; COHORT ANALYSIS; EMERGENCY WARD; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; SYMPTOMATIC INTRACRANIAL HEMORRHAGE; SYSTOLIC BLOOD PRESSURE; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CEREBRAL HEMORRHAGE; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; ETHNIC GROUPS; FEMALE; FIBRINOLYTIC AGENTS; HOSPITALS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84865591860     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.660415     Document Type: Article

References (21)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Lou M, Safdar A, Mehdiratta M, Kumar S, Schlaug G, Caplan L, et al. The HAT score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology. 2008;71:1417-1423.
4. Cucchiara B, Tanne D, Levine SR, Demchuk AM, Kasner S. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis. 2008;17: 331-333.
5. Cucchiara B, Kasner SE, Tanne D, Levine SR, Demchuk A, Messe SR, et al. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials. Stroke. 2009;40:3067-3072.
6. Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999;30:34-39.
7. Nadeau JO, Shi S, Fang J, Kapral MK, Richards JA, Silver FL, et al. tPA use for stroke in the registry of the Canadian Stroke Network. Can J Neurol Sci. 2005;32:433-439.
8. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282.
9. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Davalos A, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Stroke. 2008;39:3316-3322.
10. Reeves MJ, Fonarow GC, Smith EE, Pan W, Olson D, Hernandez AF, et al. Representativeness of the Get With The Guidelines-Stroke registry: comparison of patient and hospital characteristics among Medicare beneficiaries hospitalized with ischemic stroke. Stroke. 2012;43:44-49.
11. Cucchiara B, Kasner S, Tanne D, Levine S, Demchuk A, Messe S, et al. Validation assessment of risk scores to predict postthrombolysis intrace-rebral haemorrhage. Int J Stroke. 2011;6:109-111.
12. Tsivgoulis G, Saqqur M, Barreto A, Demchuk AM, Ribo M, Rubiera M, et al. Validity of hat score for predicting symptomatic intracranial hemorrhage in acute stroke patients with proximal occlusions: data from randomized trials of sonothrombolysis. Cerebrovasc Dis. 2011;31:471-476.
13. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928-935.
14. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian alteplase for stroke effectiveness study. J Neurol Neurosurg Psychiatry. 2006; 77:826-829.
15. Tsivgoulis G, Frey JL, Flaster M, Sharma VK, Lao AY, Hoover SL, et al. Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke. 2009;40:3631-3634.
16. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: Retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009; 40:2442-2449.
17. Prabhakaran S, Rivolta J, Vieira JR, Rincon F, Stillman J, Marshall RS. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2010;67:559-563.
18. Seet RC, Zhang Y, Moore SA, Wijdicks EF, Rabinstein AA. Subthera-peutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke. 2011;42:2333-2335.
19. Vergouwen MD, Casaubon LK, Swartz RH, Fang J, Stamplecoski M, Kapral MK. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke. 2011;42:1041-1045.
20. Hermann A, Dzialowski I, Koch R, Gahn G. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke? J Neurol Sci. 2009; 284:155-157.
21. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study investigators. Lancet. 1998;352:1245-1251.